Loading stock data…
NovoCure Limited (NVCR)
$16.85-1.09 (-6.08%)
Market ClosedLast close Sep 8
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NovoCure Limited in the Healthcare sector is trading at $16.85 with a market capitalization of $2.0B. Wall Street consensus targets $27.14 (7 analysts), implying a +61.1% move over the next 12 months. The stock is currently 21% below its 52-week high of $21.45, remaining 17.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +61.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $183.58M↑ | $174.06M↓ | $174.35M↑ | $167.20M↑ | $158.81M |
| Gross Profit | $142.48M↑ | $135.13M↑ | $132.19M↑ | $122.47M↑ | $117.33M |
| Operating Income | -$10.56M↑ | -$67.42M↓ | -$40.39M↓ | -$36.02M↑ | -$39.52M |
| Net Income | -$15.66M↑ | -$71.14M↓ | -$24.50M↑ | -$37.27M↑ | -$40.14M |
Peer Comparison
JNJUNHPFE
Fundamentals
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.98
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.94%
Volume
Today's trading volume
1.46M
Recent News
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Which Medtech Giant Would Buy Inspire Medical Systems?
The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.